Project Grant R00AG071667
Award Date
9/1/24
Completion Date
5/31/27
Dollars Obligated
$249K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,380,018 to the Regents of the University of Michigan to conduct research on the impact of type 2 diabetes and prediabetes on cognitive decline and Alzheimer's disease risk over the life course. The research team will quantify how cumulative hyperglycemia and diabetes management affect cognitive trajectories and Alzheimer's disease risk, and identify potential mechanisms linking...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $720,621 to the University of Massachusetts Medical School to investigate the role of peripheral insulin resistance and inflammation in Alzheimer's disease (AD) pathogenesis. The key objectives are to:
Define age-related changes in metabolism and inflammation in peripheral organs and the brain during AD-relevant neurodegeneration in a mouse model. This includes measuring organ-specific...
This federal Project Grant award for $218,261, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to advance the understanding of the molecular connection between obesity and Alzheimer's disease (AD). The principal investigator (PI) at the University of Virginia (UVA) will conduct a two-year exploratory study to:
Genetically identify the molecular pathways through which obesity activates the MOAG-4 protein in neuronal cells of the model...
The National Institute on Aging (NIA) awarded a $508,525 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic to investigate the role of adipose senescent cells in cognitive function and Alzheimer's disease progression. The funding will support research to determine if the aging- or obesity-driven accumulation of senescent cells in adipose tissue contributes to cognitive deficits and neurodegeneration, including Alzheimer's-related dysfunction, through endocrine effects. The research...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $787,390 to Rush University Medical Center to examine the relationship between diet, neuroinflammation, brain oxidative stress, and plasma neurodegenerative biomarkers in a diverse population. The goal is to elucidate the link between diet and Alzheimer's disease/age-related dementias (AD/ADRD).
The project will leverage four longitudinal community cohorts to collect new data and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $405,849 will fund research at Keck Graduate Institute of Applied Life Sciences in Claremont, CA to investigate the impact of obesity-induced liver dysfunction on the development of Alzheimer's disease pathology. The key objectives are to: 1) Examine how obesity-driven changes in liver amyloid-beta processing and clearance affect brain amyloid levels and Alzheimer's disease markers in...
The National Institute on Aging (NIA) awarded a $622,401 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the University of Southern California (USC) Department of Contracts and Grants Division. The 5-year grant, commencing on January 1, 2025, aims to develop sophisticated AI models and causal analysis techniques to elucidate the spatial and temporal patterns of brain biomarker changes associated with Alzheimer's disease and related dementias (ADRD).
Specifically,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,400 to Nova Southeastern University to evaluate the therapeutic potential of three compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model of comorbid Alzheimer's disease and obesity/prediabetes. The 3-year project, running from December 2024 to November 2027, will assess the compounds' impact on cognitive-behavioral function,...
This $2,085,904 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the role of glycated tau and advanced glycation end products (AGEs) in the pathology, neurotoxicity, aggregation, and neuroinflammation associated with Alzheimer's disease (AD). The 5-year project, commencing on May 1, 2024, will be conducted by the University of Colorado and aims to provide molecular-level insights into the connections between type 2...
This $831,872 Project Grant awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) aims to investigate the role of the cGAS-STING pathway and its crosstalk with the endoplasmic reticulum (ER)-associated degradation (ERAD) system in the pathogenesis of Alzheimer's disease (AD).
The primary awardee is the University of Virginia, which will collaborate with researchers at the University of Southern California to delineate how this ERAD-STING...